Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07789522 Elranatamab Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07789522 Elranatamab Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07789522 clinical trial report covering Elranatamab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791043 Efimosfermin alfa Liver Diseases, Alcoholic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791043 Efimosfermin alfa Liver Diseases, Alcoholic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791043 clinical trial report covering Efimosfermin alfa, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600131102 Adebrelimab Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600131102 Adebrelimab Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
ChiCTR2600131102 clinical trial report covering Adebrelimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07789873 MRZ-99030 Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07789873 MRZ-99030 Alzheimer Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07789873 clinical trial report covering MRZ-99030, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791654 MWN-109 Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791654 MWN-109 Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791654 clinical trial report covering MWN-109, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791537 MWN-109 Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791537 MWN-109 Prediabetic State Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791537 clinical trial report covering MWN-109, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791524 MWN-109 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791524 MWN-109 Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791524 clinical trial report covering MWN-109, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07793318 TR115 recurrent gastric cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07793318 TR115 recurrent gastric cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793318 clinical trial report covering TR115, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07791602 Camrelizumab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07791602 Camrelizumab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07791602 clinical trial report covering Camrelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07793253 Daraxonrasib Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07793253 Daraxonrasib Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793253 clinical trial report covering Daraxonrasib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07792239 Budiodarone Atrial Fibrillation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07792239 Budiodarone Atrial Fibrillation Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07792239 clinical trial report covering Budiodarone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07793071 Thiamine Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07793071 Thiamine Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
1 September 2026
NCT07793071 clinical trial report covering Thiamine Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →